Cargando…

Implementing an automated monitoring process in a digital, longitudinal observational cohort study

BACKGROUND: Clinical data collection requires correct and complete data sets in order to perform correct statistical analysis and draw valid conclusions. While in randomized clinical trials much effort concentrates on data monitoring, this is rarely the case in observational studies- due to high num...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lindner, Lisa, Weiß, Anja, Reich, Andreas, Kindler, Siegfried, Behrens, Frank, Braun, Jürgen, Listing, Joachim, Schett, Georg, Sieper, Joachim, Strangfeld, Anja, Regierer, Anne C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262053/ https://www.ncbi.nlm.nih.gov/pubmed/34233730 http://dx.doi.org/10.1186/s13075-021-02563-2

Ejemplares similares

Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers
por: Weiß, Anja, et al.
Publicado: (2014)

Comparison of patients with axial PsA and patients with axSpA and concomitant psoriasis: an analysis of the German register RABBIT-SpA
por: Regierer, Anne Constanze, et al.
Publicado: (2023)

Course of patients with juvenile spondyloarthritis during 4 years of observation, juvenile part of GESPIC
por: Weiß, Anja, et al.
Publicado: (2017)

Depressive symptoms are associated with fatigue, poorer functional status and less engagement in sports in axSpA and PsA: an analysis from the RABBIT-SpA cohort
por: Reich, Andreas, et al.
Publicado: (2023)

The relationship between inflammation and new bone formation in patients with ankylosing spondylitis
por: Baraliakos, Xenofon, et al.
Publicado: (2008)

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, Xenofon, et al.
Publicado: (2005)

Sustainability of Rituximab Therapy in Different Treatment Strategies: Results of a 3-Year Followup of a German Biologics Register
por: Richter, Adrian, et al.
Publicado: (2014)

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab
por: Listing, Joachim, et al.
Publicado: (2015)

Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years
por: Baraliakos, Xenofon, et al.
Publicado: (2013)

Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care
por: Poddubnyy, Denis, et al.
Publicado: (2018)

Health-related quality of life in patients with long-standing rheumatoid arthritis in the era of biologics: data from the German biologics register RABBIT
por: Gerhold, Kerstin, et al.
Publicado: (2015)

High burden of polypharmacy and comorbidity in persons with psoriatic arthritis: an analysis of claims data, stratified by age and sex
por: Albrecht, Katinka, et al.
Publicado: (2023)

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT
por: Strangfeld, Anja, et al.
Publicado: (2010)

Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort
por: Baganz, Lisa, et al.
Publicado: (2017)

Corrigendum to: Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis
por: Schäfer, Martin, et al.
Publicado: (2020)

Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis
por: Schäfer, Martin, et al.
Publicado: (2020)

33 Jahre DRFZ: Epidemiologie und Versorgungsforschung
por: Strangfeld, Anja, et al.
Publicado: (2022)

Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment
por: Appel, Heiner, et al.
Publicado: (2008)

Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort
por: Protopopov, Mikhail, et al.
Publicado: (2017)

Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register
por: Listing, Joachim, et al.
Publicado: (2006)

Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis
por: Meissner, Yvette, et al.
Publicado: (2016)

Study protocol: Comparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of Structural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-label randomized controlled multicenter trial
por: Proft, Fabian, et al.
Publicado: (2017)

Systematisches Review zur Schätzung der Prävalenz entzündlich rheumatischer Erkrankungen in Deutschland
por: Albrecht, Katinka, et al.
Publicado: (2023)

Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial
por: Hartl, Agnes, et al.
Publicado: (2017)

Body mass index distribution in rheumatoid arthritis: a collaborative analysis from three large German rheumatoid arthritis databases
por: Albrecht, Katinka, et al.
Publicado: (2016)

Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years
por: Baraliakos, X, et al.
Publicado: (2005)

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-α therapy and other novel approaches
por: Braun, Juergen, et al.
Publicado: (2002)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
por: Braun, Juergen, et al.
Publicado: (2023)

Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, X, et al.
Publicado: (2005)

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab
por: Baraliakos, X, et al.
Publicado: (2005)

Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project
por: Mercer, Louise K, et al.
Publicado: (2017)

Correction: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, Xenofon, et al.
Publicado: (2005)

Two-year follow-up results after re-administration of etanercept in active ankylosing spondylitis
por: Baraliakos, X, et al.
Publicado: (2005)

Canakinumab for Treatment of Adult-Onset Still’s Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial
por: Kedor, Claudia, et al.
Publicado: (2020)

Automated measurement of longitudinal psb emittances
por: Reich, KH
Publicado: (1977)

Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial
por: Proft, Fabian, et al.
Publicado: (2021)

Developments in the scientific and clinical understanding of the spondyloarthritides
por: Sieper, Joachim
Publicado: (2009)

Neues aus dem RABBIT-Register
por: Meißner, Yvette, et al.
Publicado: (2021)

Geschlechtsspezifische Unterschiede in Diagnostik und Therapie entzündlich-rheumatischer Erkrankungen
por: Albrecht, Katinka, et al.
Publicado: (2023)

Perspektiven für die rheumatologische Versorgungsforschung am Deutschen Rheuma-Forschungszentrum
por: Albrecht, K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_flctkgg7empottoo8du97klu9c